Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher

Prabhudas Lilladher has come out with its fourth quarter (January-March’ 19) earnings estimates for the Pharma sector. The brokerage house expects Glenmark Pharmaceuticals to report net profit at Rs. 196.4 crore up 30% year-on-year (up 68.8% quarter-on-quarter).

Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 2 percent Y-o-Y (down 25.9 percent Q-o-Q) to Rs. 288.7 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.